Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Cambrex Corporation
Type
Public
Traded as NYSE: CBM
S&P 600 Component
Industry Pharmaceuticals
Founded New Jersey (1981)
Headquarters East Rutherford, NJ
Key people
Steven M. Klosk, CEO, President,
Revenue Increase 433.9 million USD (2015)
Net income
Increase 57.2 million USD (2015)
Total assets Increase 505.5 million USD (2015)
Total equity Increase 310.8 million USD (2015)
Number of employees
1,200+
Website www.cambrex.com

Cambrex Corporation is a life sciences company that provides products and services for small molecule active pharmaceutical ingredients (APIs).

Cambrex has cGMP manufacturing facilities in the US (Charles City, IA), Europe (Karlskoga, Sweden, Milan, Italy and Hyderabad, India, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.

In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.

Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco.

Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. The firm acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In 2014, they acquired Zenara Pharma to enhance its drug product formulation capabilities, including Nicotine Replacement Therapy products.Cambrex Corporation has agreed to acquire Pharma Core Inc, a private company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approx $25 million

Investment goal date:
Dividends reinvested
Cambrex Corporation CBM report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-01
--
--
Q4 2017
2018-02-06
--
--
Q4 2017
2018-02-01
--
--
Q3 2017
2017-11-07
0.5500
0.5200
Q3 2017
2017-11-02
--
--
Q2 2017
2017-08-04
0.7600
0.7500
Q1 2017
2017-05-04
0.6800
0.6300
Q4 2016
2017-02-03
1.2300
1.1500
Q3 2016
2016-11-04
0.4700
0.4200
Q2 2016
2016-07-28
0.6800
0.6300
Q1 2016
2016-04-29
0.5000
0.4500
Q4 2015
2016-02-09
1.0100
0.5300
Q3 2015
2015-11-03
0.4000
0.3600
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
800591
Bank of New York Mellon Corp
1646618
BlackRock Fund Advisors
2503877
BlackRock Inc.
4002955
BlackRock Institutional Trust Company, N.A.
824263
Clearbridge Investments, LLC
971174
CONGRESS ASSET MANAGEMENT CO /MA
1193123
DIMENSIONAL FUND ADVISORS LP
1318492
FMR LLC
899086
Invesco Ltd.
588079
Ranger Investment Management, L.P.
607519
STATE STREET CORP
742151
Vanguard Group, Inc
3138934
WADDELL & REED FINANCIAL INC
599990
WELLS FARGO & CO/MN
1313140
Major Shareholders
Name Relationship
Total Shares
Holding stocks
DIXON ROSINA B
0.2100% (63570)
CBM / CHD /
TOMBROS PETER G
0.0800% (24029)
CBM / NPSP /
HARRIGAN KATHRYN
0.1900% (58909)
CBM /
MILLER JOHN R
0.1200% (35306)
CBM /
GLASSELL CLAES
0.0100% (2517)
CBM / CERS /
KLOSK STEVEN M
0.2700% (83328)
CBM / NBS /
RUSSOLO PAOLO
0.2200% (67085)
CBM /
HENDRIX LEON J JR
0.2200% (67301)
CBM /
BETHUNE DAVID R
0.0700% (21116)
CBM / FHCO /
KAUFTHAL ILAN
0.1900% (58187)
BTH / CBM /
KORB WILLIAM B
0.0700% (20562)
CBM /
SARGEN GREGORY
0.0700% (20000)
CBM /
SARGEN GREGORY
0.1600% (50000)
CBM /
Cavanagh Shawn
0.0600% (17658)
CBM /
Yanai Shlomo
0.0400% (11842)
CBM / PRGO / SGNT /
% ()